Explore Hub
Comprehensive coverage and timeline for Moderna. Aggregated from 7 sources with 7 articles.
7 articles · 7 sources · Coverage since 8/6/2026
How Moderna coverage has developed over time.
Topics frequently covered alongside Moderna.
Image: NBC News• The FDA approved mFlusiva, the first mRNA-based flu vaccine developed by Moderna, on Wednesday. • The vaccine is approved for adults aged 50 to 65 and those 65 and older, with late-stage trials showing it is approximately 27% more effective than standard flu shots. • This approval is significant as it applies the same messenger RNA platform used in Pfizer and Moderna's COVID-19 vaccines to seasonal influenza.
nbcnews.com• Moderna has launched a first-in-human Phase 1 clinical trial (NCT07737717) for mRNA-1469, an investigational vaccine targeting the Bundibugyo ebolavirus (BDBV). • The study is being conducted across three sites in Canada and aims to enroll approximately 80 healthy adult participants to evaluate safety, tolerability, and immunogenicity. • This development is critical because while vaccines exist for Zaire ebolavirus, there are currently no approved vaccines to protect against BDBV, which has caused outbreaks in the Democratic Republic of the Congo.
biospace.com
Image: Global News• Health Canada has approved a Phase I clinical trial for Moderna’s mRNA vaccine candidate targeting the Bundibugyo virus, a species of Ebola. • Canada becomes the second nation to authorize this trial, following a similar approval in the United Kingdom. • The move comes after the World Health Organization declared the current outbreak a public health emergency of international concern on May 17.
globalnews.ca• The U.S. FDA has approved Moderna's first mRNA-based influenza vaccine specifically for adults aged 50 and older. • This decision follows a reversal of a previous refusal and leverages mRNA technology that was rapidly accelerated and proven safe during the COVID-19 pandemic. • The approval is significant as it expands the use of mRNA technology to combat seasonal diseases, while Health Canada is currently considering its own approval of the shot.
cbc.ca• The FDA has approved Moderna's mFLUSIVA, the first seasonal influenza vaccine utilizing mRNA technology to receive official authorization. • The vaccine is specifically approved for use in adults aged 50 and older, marking a significant milestone for the drugmaker's mRNA platform. • This approval is critical as it demonstrates the potential for mRNA technology to address broader public health challenges beyond COVID-19.
cbsnews.comThe mFlusiva vaccine for older people is first made with mRNA platform key to ending coronavirus pandemicThe Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic, Moderna, the manufacturer, said.The shot, named mFlusiva, is intended for adults aged 50 or older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late on Wednesday that it expected some of its new version to be available soon at select retailers. Continue reading...
theguardian.com
Image: Statnews• The FDA has approved Moderna’s mFlusiva, marking the first time a licensed influenza vaccine has been developed using messenger RNA (mRNA) technology. • This approval represents a significant milestone for mRNA, a platform that gained global prominence during the COVID-19 pandemic but has faced scrutiny from vaccine skeptics. • The shift to mRNA for flu shots is critical because the technology allows for faster production and potentially better matching to evolving seasonal virus strains.
statnews.com